Clinical Study to Assess Therapeutic Delay and Resolution of Induced Gingivitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S
- University of Toronto
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female volunteers aged 18-70 years
- In good general health, ASA I
- No clinical signs of gingival inflammation at >90% sites observed
- Probing Depth (PD) < 3.0 mm
- Attachment Loss (AL) = 0 mm
- No periodontal disease history
- Non-smokers
- Fluent in English
Exclusion Criteria:
- Presence of orthodontic bands.
- Presence of partial removal dentures.
- Tumour(s) of the soft or the hard tissues of the oral cavity.
- Cavitated carious lesions requiring immediate restorative treatment.
- History of allergy to consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study.
- Participation in any other clinical study or test panel with a one month period prior to entering the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Stannous fluoride test toothpaste
Currently marketed as the new Colgate Total SF containing Stannous Fluoride
|
0.454% stannous fluoride toothpaste
Other Names:
|
|
Placebo Comparator: Colgate flouride toothpaste
Colgate Dental Cream containing Stannous Sodium Fluoride
|
0.76 % Sodium MonoFluorophosphate (MFP)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bleeding Index (BOP) and Oral Inflammatory Load
Time Frame: during patient visit over the 9 weeks
|
BOP is a bleeding index standard in field, oral inflammatory load as measured by neutrophil levels in oral rinses
|
during patient visit over the 9 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael Glogauer, DDS/PhD, University of Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRO-2018-07-IND-GING-DELAY-JG
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.